NCT04668365SuspendedPhase 2
Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma
A Single Arm, Multi-center, Phase II Clinical Trial of Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma and CD79A/CD79B Genetic Abnormality
Source: ClinicalTrials.gov · Last updated 25 Apr 2025
Reason given: Data in analysis
Brief summary (registry, in English)
This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of zanubrutinib combined with standard chemotherapy in the treatment for patients with diffuse large B cell lymphoma and CD79A/CD79B genetic abnormality.
- Status (registry)
- Suspended
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 59 (estimated)
- First submitted
- 8 Dec 2020
- Start date
- 25 Dec 2020
- Primary completion date
- 20 Nov 2024
- Lead sponsor
- Henan Cancer Hospital
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT04668365
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Serious surgery and trauma less than two weeks
- Vaccination with live attenuated vaccine less than 4 weeks
Other illness
- Active malignant tumor need be treated at the same time
- Other malignant tumor history
- Systemic therapy for serious acute/chronic infection
- Congestive heart failure, uncontrolled coronary heart disease, arrhythmia and heart infarction less than 6 months
- HIV-positive, AIDS patients and untreated active hepatitis
- Patients with a history of deep vein thrombosis or pulmonary embolism less than 12 months
- Patients with a history of mental illness
Other
- Diagnosed as high-grade B-cell lymphoma, including non-specified and double-strike or triple-strike
- Diagnosed as grey-zone lymphoma
- Diagnosed as primary mediastinal large B-cell lymphoma
- Diagnosed as CD20 negative diffuse large B-cell lymphoma
- Researchers determine unsuited to participate in this trial
Who the study is looking for
- Age between 18 to 75 years old (including 18 and 75)
- Diagnosed as diffuse large B cell lymphoma
- CD79A/CD79B genetic abnormality
- Subjects with untreated or relapsed/refractory DLBCL
- Having at least one measurable lesions
- World health organization-Eastern Cooperative Oncology Group Performance Status (ECOG) 0-1
- Life expectancy no less than 3 months
- enough main organ function
- Pregnancy test within 7 days must be negative for women of childbearing period, and appropriate measures should be taken for contraception for women in childbearing period during the study and six months after this study
- Agreeing to sign the written informed consents
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university | Zhengzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.